视网膜静脉阻塞性黄斑水肿的治疗进展
Progress in the Treatment of Retinal Vein Obstructive Macular Edema
DOI: 10.12677/ACM.2021.118525, PDF,   
作者: 闫 莎, 霍 昭, 王 飞：延安大学附属医院，眼科，陕西 延安
关键词: 视网膜静脉阻塞；黄斑水肿；治疗；综述；Retinal Vein Occlusion； Macular Edema； Treatment； Review
摘要: 视网膜静脉阻塞(RVO)是一种常见的血管性疾病，黄斑水肿(ME)是其常见并发症，也是引起视力下降的主要原因。随着对RVO发病机制的进一步了解和研究，黄斑部格栅样激光光凝、玻璃体腔注射激素或抗血管内皮生长因子(VEGF)药物、玻璃体切割术、视神经切开术等治疗方法成为RVO-ME治疗的主要研究方向。现就RVO-ME的治疗进展进行综述。
Abstract: Retinal vein occlusion (RVO) is a common vascular disease, and macular edema (ME) is a common complication and the main cause of vision loss. With the further understanding and research of the pathogenesis of RVO, macular grille laser photocoagulation, intravitreal injection of hormones or anti-vascular endothelial growth factor (VEGF) drugs, vitrectomy, optic neurotomy and other treatment methods are the main research directions of RVO-ME treatment. This article reviews the treatment progress of RVO-ME.
文章引用：闫莎, 霍昭, 王飞. 视网膜静脉阻塞性黄斑水肿的治疗进展[J]. 临床医学进展, 2021, 11(8): 3592-3598. https://doi.org/10.12677/ACM.2021.118525

参考文献

[1] Li, J., Paulus, Y.M., Shuai, Y., et al. (2017) New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Etinal Vein Occlusion. Journal of Ophthalmology, 2017, Article ID: 4936924. [Google Scholar] [CrossRef] [PubMed]
[2] McIntosh, R.L., Rogers, S.L., Lim, L., et al. (2010) History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology, 117, 1113-1123.
[3] Awdeh, R.M., Elsing, S.H., Deramo, V.A., et al. (2010) Vision-Related Quality of Life in Persons with Unilateral Branch Retinal Vein Occlusion Using the 25-Item National Eye Institute Visual Function Questionnaire. British Journal of Ophthalmology, 94, 319-323. [Google Scholar] [CrossRef] [PubMed]
[4] Deramo, V.A., Cox, T.A., Syed, A.B., et al. (2003) Vision-Related Quality of Life in People with Central Retinal Vein Occlusion Using the 25-Item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology, 121, 1297-1302. [Google Scholar] [CrossRef] [PubMed]
[5] Coscas, G., Loewenstein, A., Augustin, A., et al. (2011) Management of Retinal Vein Occlusion-Consensus Document. Ophthalmologica, 226, 4-28. [Google Scholar] [CrossRef] [PubMed]
[6] Rouvas, A., Petrou, P., Ntouraki, A., Douvali, M., Ladas, I. and Vergados, I. (2010) Intravitreal Ranibizumab (Lucentis) for Branch Retinal Vein Occlusion-Induced Macular Edema. Retina, 30, 893-902.
[7] Yao, H., Wang, T., Deng, J., et al. (2014) The Development of Blood-Retinal Barrier during the Interaction of Astrocytes with Vascular Wall Cells. Neural Regeneration Research, 9, 1047-1054.
[8] Díaz-Cornguez, M., Ramos, C. and Antonetti, D.A. (2017) The Inner Blood-Retinal Barrier: Cellular Basis and Development. Vision Research, 139, 123-137.
[9] Klaassen, I., Van Noorden, C.J.F., Schlingemann, RO. (2013) Molecular Basis of the Inner Blood-Retinal Barrier and Its Breakdown in Diabetic Macular Edema and Other Pathological Conditions. Progress in Retinal and Eye Research, 34, 19-48. [Google Scholar] [CrossRef] [PubMed]
[10] Cunha-Vaz, J. (2017) The Blood-Retinal Barrier in the Management of Retinal Disease: Euretina Award Lecture. Ophthalmologica, 237, 1-10. [Google Scholar] [CrossRef] [PubMed]
[11] Gallina, D., Zelinka, C.P., Cebulla, C.M., et al. (2015) Activation of Glucocorticoid Receptors in Müller Glia is Protective to Retinal Neurons and Suppresses Microglial Reactivity. Experimental Neurology, 273, 114-125. [Google Scholar] [CrossRef] [PubMed]
[12] Qi, Y., Zhao, M., Bai, Y., et al. (2014) Retinal Ischemia/Reperfusion Injury Is Mediated by Toll Like Receptor 4 Activation of NLRP3 Inflammasomes. Investigative Ophthalmology & Visual Science, 55, 5466-5475. [Google Scholar] [CrossRef] [PubMed]
[13] Kirkley, K.S., Popichak, K.A., Afzali, M.F., et al. (2017) Microglia Amplify Inflammatory Activation of Astrocytes in Manganese Neurotoxicity. Journal of Neuroinflammation, 14, 99. [Google Scholar] [CrossRef] [PubMed]
[14] Wakabayashi, T., Sato, T., Hara-Ueno, C., Fukushima, Y., Sayanagi, K., Shiraki, N., et al. (2017) Retinal Microvasculature and Visual Acuity in Eyes with Branch Retinal Vein Occlusion: Imaging Analysis by Optical Coherence Tomography Angiography. Investigative Ophthalmology & Visual Science, 58, 2087-2094. [Google Scholar] [CrossRef] [PubMed]
[15] 夏洋, 周吉林, 黄永健, 邹茜, 陶黎明. 康柏西普联合激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿患者远期视力恢复的影响因素研究[J]. 眼科新进展, 2021, 41(2): 174-177.
[16] 毛新帮, 赵菊莲, 游志鹏. 视网膜血管阻塞性疾病的治疗进展[J]. 中国实用眼科杂志, 2006, 24(12): 1240-1243.
[17] 陶相宜, 郭淑玲, 董微丽. 探讨视网膜激光光凝术治疗各种眼底病的临床疗效[J]. 河北医学, 2017, 23(2): 238-240.
[18] 张承芬. 常见眼底病的光凝治疗[M]. 北京: 人民卫生出版社, 1998: 700-713.
[19] Early Treatment Diabetic Retinopathy Study Group (1985) Photocogulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study report No.1. Archives of Ophthalmology, 103, 1796-1806
[20] 郑波, 王勇, 王丽丽. 激光格栅样光凝治疗视网膜中央静脉阻塞致黄斑囊样水肿的分析[J]. 国际眼科杂志, 2011, 11(6): 1046-1048.
[21] 陈少军, 阴正勤, 杨红, 吴楠, 李世迎, 孟晓红. 曲安奈德和激光治疗静脉阻塞性黄斑水肿[J]. 国际眼科杂志, 2012, 12(11): 2154-2156.
[22] 岳建中, 夏智渝, 张安民, 杨英. IVR联合激光光凝治疗对视网膜静脉阻塞继发黄斑水肿患者VEGF、CRT、BCVA、眼压的影响[J]. 临床误诊误治, 2019, 32(4): 38-43.
[23] 姜燕荣, 王凯, 黎晓新. 曲安奈德玻璃体腔注射治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J]. 眼科研究, 2006, 4(6): 639-642.
[24] 马艳波, 王洁, 马秋莎. 曲安奈德治疗视网膜静脉阻塞继发黄斑水肿临床观察[J]. 中外医疗, 2014(22): 131-133.
[25] Haller, J.A., Bandello, F., Belfortr Blumenkranz, M.S., Gillies, M., Heier, J., et al. (2011) Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. Ophthalmology, 118, 2453-2460. [Google Scholar] [CrossRef] [PubMed]
[26] Kuppermann, B.D., Haller, J.A., Bandello, F., Loewen-Stein, A., Jiao, J., Li, X.Y., et al. (2014) Onset and Duration of Visual Acuity Improvement after Dexamethasone Intravitreal Implant in Eyes with Macular Edema Due to Retinal Vein Occlusion. Retina, 34, 1743-1749. [Google Scholar] [CrossRef] 
[27] 中国视网膜静脉阻塞地塞米松玻璃体腔植入剂研究组, 黎晓新, 王宁利, 梁小玲, 徐格致, Xiao-yan Li, Jenny Jiao, Jean Lou, Yehia Hashad. 地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性: 随机、假注射对照、多中心研究[J]. 中华眼底病杂志, 2018, 34(3): 212-220.
[28] 谷潇雅, 戴虹, 喻晓兵. 地塞米松玻璃体腔植入剂治疗视网膜静脉阻塞继发黄斑水肿一年临床观察[J]. 中华眼底病杂志, 2018, 34(3): 221-227.
[29] Noma, H., Funatsu, H., Harino, S., et al. (2011) Vitreous Inflammatory Factorsin Macular Edema with Central Retinal Vein Occlusion. Japanese Journal of Ophthalmology, 55, 248-255. [Google Scholar] [CrossRef] [PubMed]
[30] Noma, H., Mimura, T., Yasuda, K., et al. (2015) Role of Soluble Vascular Endothelial Growth Factor Receptor Signaling and Other Factors or Cytokines in Central Retinal Vein Occlusion with Macular Edema. Investigative Ophthalmology & Visual Science, 56, 1122-1128. [Google Scholar] [CrossRef] [PubMed]
[31] Ferrara, N., Damico, I., Shams, N., et al. (2006) Development of Ranibizumab. An Anti-Vascular Endothelial Growth Factor Antigen Binding Fragment, as Therapy for Neovascular Age Related Macular Degeneration. Retina, 2.
[32] 万珊珊, 杨燕宁, 邢怡桥, 满子惠, 饶卓群. 雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿的效果及安全性的系统评价[J]. 中国医药报, 2013, 10(27): 62-64, 67.
[33] 李路明, 杨少华. 雷珠单抗玻璃体内注射治疗视网膜静脉阻塞黄斑水肿[J]. 世界复合医学, 2020, 6(10): 171-173.
[34] 沈宵, 常青. 视网膜静脉阻塞抗血管内皮生长因子治疗研究进展[J]. 中华眼底病杂志, 2013, 29(6): 634-637.
[35] Epstein, D.L., Algvere, P.V., von Wendt, G., et al. (2012) Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: Aprospective, Randomized, Double-Masked Clinical Study. Ophthalmology, 119, 2587-2591. [Google Scholar] [CrossRef] [PubMed]
[36] Averyrl, Castellarinaa, Steinlenc, Dhootds, Pieramicidj, Seer, et al. (2017) Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina, 37, 1847-1858. [Google Scholar] [CrossRef] 
[37] 吴冠男, 张笑天, 何广辉, 董蒙, 高翔, 王梦, 陈松. 阿柏西普治疗视网膜静脉阻塞继发黄斑水肿的视网膜微血管改变及视力预后分析[J]. 中华眼底病杂志, 2021, 37(4): 290-297.
[38] Scott, I.U., Oden, N.L., Van Veldhuisen, P.C., et al. (2019) Month 24 Outcomes after Treatment Initiation with Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A secondary Analysis of the SCORE2 Randomized Clinical Trial. JJAMA Ophthalmology, 137, 1389-1398. [Google Scholar] [CrossRef] [PubMed]
[39] Casselholm de Salles, M., Amrén, U., Kvanta, A., et al. (2019) Injection Frequency of Aflibercept versus Ranibizumab in a Treat-and-Extend Regimen for Central Retinal Vein Occlusion: A Randomized Clinical Trial. Retina, 39, 1370-1376. [Google Scholar] [CrossRef] 
[40] 张军军, 张美霞. 湿性年龄相关性黄斑变性治疗方法的新选择[J]. 中华实验眼科杂志, 2012, 30(11): 961-964.
[41] 郭超. 康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2019.
[42] 赵宏锟, 吴敏. 康柏西普不同给药方案治疗视网膜分支静脉阻塞继发黄斑水肿[J]. 国际眼科杂志, 2019, 19(4): 567-570.
[43] Nishida, A., Kojima, H., Kameda, T., Mandai, M. and Kurimo-To, Y. (2017) Five-Year Outcomes of Pars Plana Vitrectomy for Macular Edema Associated with Branch Retinal Vein Occlusion. Clinical Ophthalmology, 11, 369-375. [Google Scholar] [CrossRef] 
[44] 张燕. 玻璃体切割联合内界膜剥离治疗RVO继发黄斑水肿[J]. 国际眼科杂志, 2012, 12(8): 1581-1582.
[45] 邵毅, 张雨晴, 周琼. 视网膜静脉阻塞诊疗规范——2019年欧洲视网膜专家协会指南解读[J]. 眼科新进展, 2020, 40(6): 501-504.

为你推荐